

Table SII. TSQM subscores for different treatment modalities and specific systemic antipsoriatic medications currently used

	Efficacy Mean (SD)	Adverse events Mean (SD)	Convenience Mean (SD)	Global satisfaction Mean (SD)
Treatment modalities				
Topical therapy	51.5 (20.4)	91.2 (19.3)	69.7 (21.5)	54.4 (21.4)
Phototherapy	47.9 (23.7)	88 (26.1)	67.1 (19)	57.7 (20.5)
Traditional systemic therapy	58.8 (32.4)	78.2 (29.1)	81.3 (22.3)	69.7 (23.4)
Biologicals	71.5 (26.3)	88.4 (19.8)	83.7 (15.9)	79.7 (16.6)
	$p < 0.001$	$p = 0.023$	$p < 0.001$	$p < 0.001$
Systemic medications				
Acitretin	73.1 (22.9)	89.6 (18)	94.4 (8.6)	81 (16.7)
Fumaric acid esters	62.8 (32.3)	83.2 (24.9)	84.3 (21.5)	74.4 (21.6)
Methotrexate	53.9 (35.6)	76.1 (29.7)	75.5 (22.3)	66.8 (22.6)
Adalimumab	67.7 (30.2)	90.3 (19.8)	86.9 (14.8)	78.1 (21)
Etanercept	57.9 (21.5)	83.0 (23.9)	83.3 (16.7)	74.5 (10.8)
Infliximab	65.8 (26.5)	89.4 (17.4)	71.4 (10.6)	73.6 (13.5)
Ustekinumab	84 (21.9)	89.3 (19.7)	88.9 (16.3)	88 (10)
Combination therapy ^a	54 (31.7)	69.9 (36.5)	69.2 (23.7)	59.1 (28.8)
	$p = 0.037$	$p = 0.192$	$p = 0.005$	$p = 0.003$

Each of the 4 subscales of the Treatment Satisfaction Questionnaire for Medication (TSQM) ranges from 0 to 100. Differences between TSQM subscores of all treatment modalities or all systemic medications were tested for significance with analysis of variance (ANOVA).

^aDetails on combination therapies are shown in Table SI¹.

SD: standard deviation.